NGM Biopharmaceuticals Raises $122M in Series A Funding: Revolutionizing Medicine for Unmet Patient Needs

NGM Biopharmaceuticals is immensely thrilled to announce the successful completion of a $122 million funding round, positioning the company for continued growth and innovation in the biopharmaceutical sector. As a pioneering organization dedicated to discovering and developing novel, life-changing medicines, NGM Bio leverages its unique biology-centric drug discovery approach to address the unmet needs of patients affected by various diseases. The substantial funding will be instrumental in bolstering NGM Bio’s commitment to advancing its promising pipeline, which currently boasts four programs in active clinical development. This infusion of capital will not only enhance the company’s research capabilities and accelerate the progress of its therapeutic candidates but also underscores the confidence investors have in NGM Bio’s vision and operational excellence. Our proprietary insights, derived from an intricate understanding of complex disease-associated biology and robust protein engineering, empower us to create novel treatments that have the potential to redefine patient care. As we continue to explore the frontiers of life-changing science, this funding will help us achieve our goal of becoming one of the most productive R&D engines in the biopharmaceutical industry. At NGM Bio, we remain steadfast in our mission to improve lives through innovative therapies, and we are excited for the journey ahead. For more information about our ongoing projects and future initiatives, visit us at www.ngmbio.com.